- Pyridopyrimidinones
-
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X′ have the designations cited in patent claim 1. Said c
- -
-
-
- Sulfonamides
-
Compounds of the formula (I), in which R6, R7, R8, R9 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for t
- -
-
-
- SULFONAMIDES
-
The invention relates to compounds of formula (I) in which R6, R7, R8, R9 and X have the meanings cited in Claim 1. These compounds are inhibitors of tyrosinkinases, particularly TIE-2, and Raf kinases and can, among other things, be used for treating tumors.
- -
-
-
- PYRIDOPYRIMIDINONES
-
The invention relates to compounds of formula (I) wherein R1, R2 , R3 , R4 , R5, R6 , R7 , R8, R9, X and X' have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumours.
- -
-
Page/Page column 64
(2008/06/13)
-
- Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides
-
A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2′, C3′, C4′ and/or C5′ position. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both purine nucleoside analogs and the corresponding prodrugs are employed in the reduction of growth of neoplastic cells.
- -
-
-
- Synthesis and cytotoxicity of 4-amino-5-oxopyrido[2,3-d]pyrimidine nucleosides
-
A number of nucleoside analogues have been either used clinically as anticancer drugs or evaluated in clinical studies, while new nucleoside analogues continue to show promise. In this article, we report synthesis and cytotoxicity of a series of new pyrid
- Girardet,Gunic,Esler,Cieslak,Pietrzkowski,Wang
-
p. 3704 - 3713
(2007/10/03)
-